These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 28951465)

  • 1. Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma.
    Yuan J; Jiang YY; Mayakonda A; Huang M; Ding LW; Lin H; Yu F; Lu Y; Loh TKS; Chow M; Savage S; Tyner JW; Lin DC; Koeffler HP
    Cancer Res; 2017 Dec; 77(23):6614-6626. PubMed ID: 28951465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.
    Jiang YY; Lin DC; Mayakonda A; Hazawa M; Ding LW; Chien WW; Xu L; Chen Y; Xiao JF; Senapedis W; Baloglu E; Kanojia D; Shang L; Xu X; Yang H; Tyner JW; Wang MR; Koeffler HP
    Gut; 2017 Aug; 66(8):1358-1368. PubMed ID: 27196599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer.
    Yang Y; Jiang D; Zhou Z; Xiong H; Yang X; Peng G; Xia W; Wang S; Lei H; Zhao J; Qian Z; Wu S; Pang J
    Cell Oncol (Dordr); 2021 Aug; 44(4):871-887. PubMed ID: 33905040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer.
    Lu P; Geng J; Zhang L; Wang Y; Niu N; Fang Y; Liu F; Shi J; Zhang ZG; Sun YW; Wang LW; Tang Y; Xue J
    Oncogene; 2019 May; 38(20):3932-3945. PubMed ID: 30692639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
    Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
    Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
    [No Abstract]   [Full Text] [Related]  

  • 6. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.
    Cayrol F; Praditsuktavorn P; Fernando TM; Kwiatkowski N; Marullo R; Calvo-Vidal MN; Phillip J; Pera B; Yang SN; Takpradit K; Roman L; Gaudiano M; Crescenzo R; Ruan J; Inghirami G; Zhang T; Cremaschi G; Gray NS; Cerchietti L
    Nat Commun; 2017 Jan; 8():14290. PubMed ID: 28134252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway.
    Chow PM; Chang YW; Kuo KL; Lin WC; Liu SH; Huang KH
    Cancer Lett; 2021 Jun; 507():70-79. PubMed ID: 33741425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer.
    Zhang Z; Peng H; Wang X; Yin X; Ma P; Jing Y; Cai MC; Liu J; Zhang M; Zhang S; Shi K; Gao WQ; Di W; Zhuang G
    Mol Cancer Ther; 2017 Sep; 16(9):1739-1750. PubMed ID: 28572168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.
    Sun J; Zhang Q; Sun X; Xue A; Gao X; Shen K
    Cell Commun Signal; 2022 Sep; 20(1):138. PubMed ID: 36076237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
    Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
    J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263.
    Huang T; Ding X; Xu G; Chen G; Cao Y; Peng C; Shen S; Lv Y; Wang L; Zou X
    Cell Death Dis; 2019 Aug; 10(8):602. PubMed ID: 31399555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells
    Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S
    Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
    Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ΔNp63α is a super enhancer-enriched master factor controlling the basal-to-luminal differentiation transcriptional program and gene regulatory networks in nasopharyngeal carcinoma.
    Cai J; Chen S; Yi M; Tan Y; Peng Q; Ban Y; Yang J; Li X; Zeng Z; Xiong W; McCarthy JB; Li G; Li X; Xiang B
    Carcinogenesis; 2020 Sep; 41(9):1282-1293. PubMed ID: 31826234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.
    Hsu CL; Lui KW; Chi LM; Kuo YC; Chao YK; Yeh CN; Lee LY; Huang Y; Lin TL; Huang MY; Lai YR; Yeh YM; Fan HC; Lin AC; Lu YJ; Hsieh CH; Chang KP; Tsang NM; Wang HM; Chang AY; Chang YS; Li HP
    J Exp Clin Cancer Res; 2018 Sep; 37(1):233. PubMed ID: 30236142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.
    Sun B; Mason S; Wilson RC; Hazard SE; Wang Y; Fang R; Wang Q; Yeh ES; Yang M; Roberts TM; Zhao JJ; Wang Q
    Oncogene; 2020 Jan; 39(1):50-63. PubMed ID: 31462705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
    Zhong L; Yang S; Jia Y; Lei K
    J Cell Biochem; 2018 Dec; 119(12):9742-9751. PubMed ID: 30145799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.
    Nagaraja S; Vitanza NA; Woo PJ; Taylor KR; Liu F; Zhang L; Li M; Meng W; Ponnuswami A; Sun W; Ma J; Hulleman E; Swigut T; Wysocka J; Tang Y; Monje M
    Cancer Cell; 2017 May; 31(5):635-652.e6. PubMed ID: 28434841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Super-enhancer driven SOX2 promotes tumor formation by chromatin re-organization in nasopharyngeal carcinoma.
    Liu SX; Wang C; Lin RB; Ding WY; Roy G; Wang HB; Yang T; Liu Q; Luo YL; Jin SL; Zeng MS; Zhao B; Zhong Q
    EBioMedicine; 2023 Dec; 98():104870. PubMed ID: 37967508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma.
    Eliades P; Abraham BJ; Ji Z; Miller DM; Christensen CL; Kwiatkowski N; Kumar R; Njauw CN; Taylor M; Miao B; Zhang T; Wong KK; Gray NS; Young RA; Tsao H
    J Invest Dermatol; 2018 Jul; 138(7):1582-1590. PubMed ID: 29408204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.